← Oncology Approval Tracker

FDA DECISION ·

Rubraca

rucaparib · pharmaand GmbH

Traditional approvalTraditional conversionProstate cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

For adults with metastatic castration-resistant prostate cancer with a deleterious germline or somatic BRCA mutation confirmed by an FDA-approved companion diagnostic, after androgen receptor-directed therapy.

LAMPGEN ANALYSIS

Why it matters

TRITON3 confirmed benefit in BRCA-mutated disease and the traditional label removed the prior taxane requirement from the 2020 accelerated indication.

What research teams should watch

Capture the BRCA companion diagnostic and previous androgen receptor-directed treatment without assuming a prior taxane is required.

Related study operations checklist

See the staffing responsibilities, timing, and handoff questions for this study setting.

Metastatic castration-resistant prostate cancer

PRIMARY RECORDS

Sources